PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26224F0036Illuccix for VASD nuclear MED — Telix Pharmaceuticals (Us) Inc

Telix Pharmaceuticals (Us) Inc holds $6.9M across 17 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79722D0197. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 31, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Telix Pharmaceuticals (Us) Inc

Recipient

Oct 31, 2024

PoP end

$334K

Obligated

$490K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Telix Pharmaceuticals (Us) Inc — $90

Contract facts

Federal

Contract number36C26224F0036

Also listed as36C262-24-F-0036

Also listed as36F79722D0197-36C26224F0036

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTelix Pharmaceuticals (Us) Inc

CAGE8CP27

UEINMRHMBK4YTH7

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0197

Place of performanceDUBLIN OH

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startNov 1, 2023

PoP end (current)Oct 31, 2024

Obligated$334K

Current value$490K

Potential value$490K

ILLUCCIX FOR VASD NUCLEAR MED is a federal award for 262-Network Contract Office 22 (36C262) held by Telix Pharmaceuticals (Us) Inc. Estimated value $490K ($334K obligated). Current period of performance ends Oct 31, 2024. Last award drew 1 bidder. Place of performance: DUBLIN OH.

Recompete timing

Public

● Past PoP end (659 days ago)

Current PoP ended Oct 31, 2024 (659 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Telix Pharmaceuticals (Us) Inc — $6.9M obligated across 17 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$6.9M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C24826N0054

ILLUCCIX

$1.8M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26224F0036?

36C26224F0036 (Illuccix for VASD nuclear MED) is a 262-Network Contract Office 22 (36C262) award with a potential value of $490K, currently held by Telix Pharmaceuticals (Us) Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-24-F-0036?

36C262-24-F-0036 is the dashed form of PIID 36C26224F0036 (Illuccix for VASD nuclear MED), held by Telix Pharmaceuticals (Us) Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26224F0036?

262-Network Contract Office 22 (36C262) awarded 36C26224F0036 to Telix Pharmaceuticals (Us) Inc (potential $490K).

Who is the incumbent on 36C26224F0036?

Telix Pharmaceuticals (Us) Inc is the incumbent with $6.9M across 17 related awards in SCOUT’s public footprint. The current period of performance ends Oct 31, 2024.

When does Telix Pharmaceuticals (Us) Inc’s 36C26224F0036 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 31, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Jan 24, 2025